Postmenopausal Vaginal Atrophy Therapeutics Market Forecast to 2028 - COVID-19 Impact and Global Analysis by therapy type (Estrogen based drugs, Non-estrogen based drugs, others); Product types (Vaginal gels, Creams, Tablets, Rings, Patches, Others.); End User (Hospitals, Specialty clinics, Others.)

Report Code: TIPRE00013446 | No. of Pages: 150 | Category: Healthcare IT | Status: Upcoming

Covid
Assesing the covid-19 impact?
Get the Latest COVID-19 Analysis on this market
Request Now
Happy to join you in your fight against the COVID-19 economic pandemic!
MARKET INTRODUCTION

Postmenopausal vaginal atrophy (PVA), also referred to as postmenopausal atrophic vaginitis, caused by the vaginal walls' drying, thinning, and inflammation due to reduced estrogen levels. Women with this disorder are more vulnerable to problems of urinary system and chronic infection of vaginal linings. A variety of medications and therapies available in market that focuses on the underlying cause as well as the symptoms of the condition. These therapies also helps women to improve their quality of life. The major trends observed in this market is the shift from systemic estrogen therapies, such as vaginal gels, creams, and patches, to non-estrogenic therapies. Even so the demand for the former therapeutics appears to be high and between the topical and systemic class of estrogen products systemic class dominates the market.

MARKET DYNAMICS

Major factor driving the growth of the global Postmenopausal Vaginal Atrophy Therapeutics market is growing awareness about the therapies, technological advancements, and increasing research grants. Moreover, high unmet medical needs across the developing nations is also expected to increase the demand for Postmenopausal Vaginal Atrophy Therapeutics. However, low diagnosis rates, patent expiry of branded products and safety issues with existing therapies are some of the factors restraining the market growth.

MARKET SCOPE

The Postmenopausal Vaginal Atrophy Therapeutics market analysis to 2028 is a specialized and in-depth study of the healthcare industry with a special focus on the global market trend analysis. The report aims to provide an overview of Postmenopausal Vaginal Atrophy Therapeutics market with detailed market segmentation by therapy type, product types and end users. The Postmenopausal Vaginal Atrophy Therapeutics market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading players in Postmenopausal Vaginal Atrophy Therapeutics market and offers key trends and opportunities in the market.

MARKET SEGMENTATION

The Postmenopausal Vaginal Atrophy Therapeutics market is segmented on the basis of therapy type, product types and end users. Based on therapy type, the market is segmented as estrogen based drugs, non-estrogen based drugs and others. On the basis of product type market is segmented as vaginal gels, creams, tablets, rings, patches and others. On the basis of end users, market can be segmented as hospitals, specialty clinics and others.

REGIONAL FRAMEWORK

The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the Postmenopausal Vaginal Atrophy Therapeutics market based on various segments. It also provides market size and forecast estimates from year 2020 to 2028 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The Postmenopausal Vaginal Atrophy Therapeutics market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.

The report analyzes factors affecting Postmenopausal Vaginal Atrophy Therapeutics market from both demand and supply side and further evaluates market dynamics affecting the market during forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the Postmenopausal Vaginal Atrophy Therapeutics market in these regions.



Get more information on this report :

MARKET PLAYERS


The report covers key developments in the Postmenopausal Vaginal Atrophy Therapeutics market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from Postmenopausal Vaginal Atrophy Therapeutics market are anticipated to have lucrative growth opportunities in the future with the rising demand for Postmenopausal Vaginal Atrophy Therapeutics in the global market. Below mentioned is the list of few companies engaged in the Postmenopausal Vaginal Atrophy Therapeutics market.

The report also includes the profiles of key players in Postmenopausal Vaginal Atrophy Therapeutics market along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.

  •  Endoceutics
  •  Accord Healthcare
  •  Pfizer
  •  Novo Nordisk
  •  Teva Pharmaceuticals
  •  Shionogi and Co
  •  Bionovo, Inc.
  •  QuatRx Pharmaceutical Company
  •  Bayer AG
  •  TherapeuticsMD

The Insight Partner's dedicated research and analysis team consists of experienced professionals with advanced statistical expertise and offers various customization options in the existing study.


Get more information on this report :

TABLE OF CONTENTS

1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Postmenopausal Vaginal Atrophy Therapeutics Market - By Therapy type
1.3.2 Postmenopausal Vaginal Atrophy Therapeutics Market - By Product types
1.3.3 Postmenopausal Vaginal Atrophy Therapeutics Market - By End User
1.3.4 Postmenopausal Vaginal Atrophy Therapeutics Market - By Region
1.3.4.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. POSTMENOPAUSAL VAGINAL ATROPHY THERAPEUTICS MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. POSTMENOPAUSAL VAGINAL ATROPHY THERAPEUTICS MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. POSTMENOPAUSAL VAGINAL ATROPHY THERAPEUTICS MARKET - GLOBAL MARKET ANALYSIS
6.1. POSTMENOPAUSAL VAGINAL ATROPHY THERAPEUTICS - GLOBAL MARKET OVERVIEW
6.2. POSTMENOPAUSAL VAGINAL ATROPHY THERAPEUTICS - GLOBAL MARKET AND FORECAST TO 2028
6.3. MARKET POSITIONING/MARKET SHARE
7. POSTMENOPAUSAL VAGINAL ATROPHY THERAPEUTICS MARKET - REVENUE AND FORECASTS TO 2028 - THERAPY TYPE
7.1. OVERVIEW
7.2. THERAPY TYPE MARKET FORECASTS AND ANALYSIS
7.3. ESTROGEN BASED DRUGS
7.3.1. Overview
7.3.2. Estrogen based drugs Market Forecast and Analysis
7.4. NON-ESTROGEN BASED DRUGS
7.4.1. Overview
7.4.2. Non-estrogen based drugs Market Forecast and Analysis
7.5. OTHERS
7.5.1. Overview
7.5.2. others Market Forecast and Analysis
8. POSTMENOPAUSAL VAGINAL ATROPHY THERAPEUTICS MARKET - REVENUE AND FORECASTS TO 2028 - PRODUCT TYPES
8.1. OVERVIEW
8.2. PRODUCT TYPES MARKET FORECASTS AND ANALYSIS
8.3. VAGINAL GELS
8.3.1. Overview
8.3.2. Vaginal gels Market Forecast and Analysis
8.4. CREAMS
8.4.1. Overview
8.4.2. Creams Market Forecast and Analysis
8.5. TABLETS
8.5.1. Overview
8.5.2. Tablets Market Forecast and Analysis
8.6. RINGS
8.6.1. Overview
8.6.2. Rings Market Forecast and Analysis
8.7. PATCHES
8.7.1. Overview
8.7.2. Patches Market Forecast and Analysis
8.8. OTHERS.
8.8.1. Overview
8.8.2. Others. Market Forecast and Analysis
9. POSTMENOPAUSAL VAGINAL ATROPHY THERAPEUTICS MARKET - REVENUE AND FORECASTS TO 2028 - END USER
9.1. OVERVIEW
9.2. END USER MARKET FORECASTS AND ANALYSIS
9.3. HOSPITALS
9.3.1. Overview
9.3.2. Hospitals Market Forecast and Analysis
9.4. SPECIALTY CLINICS
9.4.1. Overview
9.4.2. Specialty clinics Market Forecast and Analysis
9.5. OTHERS.
9.5.1. Overview
9.5.2. Others. Market Forecast and Analysis
10. POSTMENOPAUSAL VAGINAL ATROPHY THERAPEUTICS MARKET REVENUE AND FORECASTS TO 2028 - GEOGRAPHICAL ANALYSIS
10.1. NORTH AMERICA
10.1.1 North America Postmenopausal Vaginal Atrophy Therapeutics Market Overview
10.1.2 North America Postmenopausal Vaginal Atrophy Therapeutics Market Forecasts and Analysis
10.1.3 North America Postmenopausal Vaginal Atrophy Therapeutics Market Forecasts and Analysis - By Therapy type
10.1.4 North America Postmenopausal Vaginal Atrophy Therapeutics Market Forecasts and Analysis - By Product types
10.1.5 North America Postmenopausal Vaginal Atrophy Therapeutics Market Forecasts and Analysis - By End User
10.1.6 North America Postmenopausal Vaginal Atrophy Therapeutics Market Forecasts and Analysis - By Countries
10.1.6.1 United States Postmenopausal Vaginal Atrophy Therapeutics Market
10.1.6.1.1 United States Postmenopausal Vaginal Atrophy Therapeutics Market by Therapy type
10.1.6.1.2 United States Postmenopausal Vaginal Atrophy Therapeutics Market by Product types
10.1.6.1.3 United States Postmenopausal Vaginal Atrophy Therapeutics Market by End User
10.1.6.2 Canada Postmenopausal Vaginal Atrophy Therapeutics Market
10.1.6.2.1 Canada Postmenopausal Vaginal Atrophy Therapeutics Market by Therapy type
10.1.6.2.2 Canada Postmenopausal Vaginal Atrophy Therapeutics Market by Product types
10.1.6.2.3 Canada Postmenopausal Vaginal Atrophy Therapeutics Market by End User
10.1.6.3 Mexico Postmenopausal Vaginal Atrophy Therapeutics Market
10.1.6.3.1 Mexico Postmenopausal Vaginal Atrophy Therapeutics Market by Therapy type
10.1.6.3.2 Mexico Postmenopausal Vaginal Atrophy Therapeutics Market by Product types
10.1.6.3.3 Mexico Postmenopausal Vaginal Atrophy Therapeutics Market by End User
10.2. EUROPE
10.2.1 Europe Postmenopausal Vaginal Atrophy Therapeutics Market Overview
10.2.2 Europe Postmenopausal Vaginal Atrophy Therapeutics Market Forecasts and Analysis
10.2.3 Europe Postmenopausal Vaginal Atrophy Therapeutics Market Forecasts and Analysis - By Therapy type
10.2.4 Europe Postmenopausal Vaginal Atrophy Therapeutics Market Forecasts and Analysis - By Product types
10.2.5 Europe Postmenopausal Vaginal Atrophy Therapeutics Market Forecasts and Analysis - By End User
10.2.6 Europe Postmenopausal Vaginal Atrophy Therapeutics Market Forecasts and Analysis - By Countries
10.2.6.1 Germany Postmenopausal Vaginal Atrophy Therapeutics Market
10.2.6.1.1 Germany Postmenopausal Vaginal Atrophy Therapeutics Market by Therapy type
10.2.6.1.2 Germany Postmenopausal Vaginal Atrophy Therapeutics Market by Product types
10.2.6.1.3 Germany Postmenopausal Vaginal Atrophy Therapeutics Market by End User
10.2.6.2 France Postmenopausal Vaginal Atrophy Therapeutics Market
10.2.6.2.1 France Postmenopausal Vaginal Atrophy Therapeutics Market by Therapy type
10.2.6.2.2 France Postmenopausal Vaginal Atrophy Therapeutics Market by Product types
10.2.6.2.3 France Postmenopausal Vaginal Atrophy Therapeutics Market by End User
10.2.6.3 Italy Postmenopausal Vaginal Atrophy Therapeutics Market
10.2.6.3.1 Italy Postmenopausal Vaginal Atrophy Therapeutics Market by Therapy type
10.2.6.3.2 Italy Postmenopausal Vaginal Atrophy Therapeutics Market by Product types
10.2.6.3.3 Italy Postmenopausal Vaginal Atrophy Therapeutics Market by End User
10.2.6.4 Spain Postmenopausal Vaginal Atrophy Therapeutics Market
10.2.6.4.1 Spain Postmenopausal Vaginal Atrophy Therapeutics Market by Therapy type
10.2.6.4.2 Spain Postmenopausal Vaginal Atrophy Therapeutics Market by Product types
10.2.6.4.3 Spain Postmenopausal Vaginal Atrophy Therapeutics Market by End User
10.2.6.5 United Kingdom Postmenopausal Vaginal Atrophy Therapeutics Market
10.2.6.5.1 United Kingdom Postmenopausal Vaginal Atrophy Therapeutics Market by Therapy type
10.2.6.5.2 United Kingdom Postmenopausal Vaginal Atrophy Therapeutics Market by Product types
10.2.6.5.3 United Kingdom Postmenopausal Vaginal Atrophy Therapeutics Market by End User
10.3. ASIA-PACIFIC
10.3.1 Asia-Pacific Postmenopausal Vaginal Atrophy Therapeutics Market Overview
10.3.2 Asia-Pacific Postmenopausal Vaginal Atrophy Therapeutics Market Forecasts and Analysis
10.3.3 Asia-Pacific Postmenopausal Vaginal Atrophy Therapeutics Market Forecasts and Analysis - By Therapy type
10.3.4 Asia-Pacific Postmenopausal Vaginal Atrophy Therapeutics Market Forecasts and Analysis - By Product types
10.3.5 Asia-Pacific Postmenopausal Vaginal Atrophy Therapeutics Market Forecasts and Analysis - By End User
10.3.6 Asia-Pacific Postmenopausal Vaginal Atrophy Therapeutics Market Forecasts and Analysis - By Countries
10.3.6.1 Australia Postmenopausal Vaginal Atrophy Therapeutics Market
10.3.6.1.1 Australia Postmenopausal Vaginal Atrophy Therapeutics Market by Therapy type
10.3.6.1.2 Australia Postmenopausal Vaginal Atrophy Therapeutics Market by Product types
10.3.6.1.3 Australia Postmenopausal Vaginal Atrophy Therapeutics Market by End User
10.3.6.2 China Postmenopausal Vaginal Atrophy Therapeutics Market
10.3.6.2.1 China Postmenopausal Vaginal Atrophy Therapeutics Market by Therapy type
10.3.6.2.2 China Postmenopausal Vaginal Atrophy Therapeutics Market by Product types
10.3.6.2.3 China Postmenopausal Vaginal Atrophy Therapeutics Market by End User
10.3.6.3 India Postmenopausal Vaginal Atrophy Therapeutics Market
10.3.6.3.1 India Postmenopausal Vaginal Atrophy Therapeutics Market by Therapy type
10.3.6.3.2 India Postmenopausal Vaginal Atrophy Therapeutics Market by Product types
10.3.6.3.3 India Postmenopausal Vaginal Atrophy Therapeutics Market by End User
10.3.6.4 Japan Postmenopausal Vaginal Atrophy Therapeutics Market
10.3.6.4.1 Japan Postmenopausal Vaginal Atrophy Therapeutics Market by Therapy type
10.3.6.4.2 Japan Postmenopausal Vaginal Atrophy Therapeutics Market by Product types
10.3.6.4.3 Japan Postmenopausal Vaginal Atrophy Therapeutics Market by End User
10.3.6.5 South Korea Postmenopausal Vaginal Atrophy Therapeutics Market
10.3.6.5.1 South Korea Postmenopausal Vaginal Atrophy Therapeutics Market by Therapy type
10.3.6.5.2 South Korea Postmenopausal Vaginal Atrophy Therapeutics Market by Product types
10.3.6.5.3 South Korea Postmenopausal Vaginal Atrophy Therapeutics Market by End User
10.4. MIDDLE EAST AND AFRICA
10.4.1 Middle East and Africa Postmenopausal Vaginal Atrophy Therapeutics Market Overview
10.4.2 Middle East and Africa Postmenopausal Vaginal Atrophy Therapeutics Market Forecasts and Analysis
10.4.3 Middle East and Africa Postmenopausal Vaginal Atrophy Therapeutics Market Forecasts and Analysis - By Therapy type
10.4.4 Middle East and Africa Postmenopausal Vaginal Atrophy Therapeutics Market Forecasts and Analysis - By Product types
10.4.5 Middle East and Africa Postmenopausal Vaginal Atrophy Therapeutics Market Forecasts and Analysis - By End User
10.4.6 Middle East and Africa Postmenopausal Vaginal Atrophy Therapeutics Market Forecasts and Analysis - By Countries
10.4.6.1 South Africa Postmenopausal Vaginal Atrophy Therapeutics Market
10.4.6.1.1 South Africa Postmenopausal Vaginal Atrophy Therapeutics Market by Therapy type
10.4.6.1.2 South Africa Postmenopausal Vaginal Atrophy Therapeutics Market by Product types
10.4.6.1.3 South Africa Postmenopausal Vaginal Atrophy Therapeutics Market by End User
10.4.6.2 Saudi Arabia Postmenopausal Vaginal Atrophy Therapeutics Market
10.4.6.2.1 Saudi Arabia Postmenopausal Vaginal Atrophy Therapeutics Market by Therapy type
10.4.6.2.2 Saudi Arabia Postmenopausal Vaginal Atrophy Therapeutics Market by Product types
10.4.6.2.3 Saudi Arabia Postmenopausal Vaginal Atrophy Therapeutics Market by End User
10.4.6.3 U.A.E Postmenopausal Vaginal Atrophy Therapeutics Market
10.4.6.3.1 U.A.E Postmenopausal Vaginal Atrophy Therapeutics Market by Therapy type
10.4.6.3.2 U.A.E Postmenopausal Vaginal Atrophy Therapeutics Market by Product types
10.4.6.3.3 U.A.E Postmenopausal Vaginal Atrophy Therapeutics Market by End User
10.5. SOUTH AND CENTRAL AMERICA
10.5.1 South and Central America Postmenopausal Vaginal Atrophy Therapeutics Market Overview
10.5.2 South and Central America Postmenopausal Vaginal Atrophy Therapeutics Market Forecasts and Analysis
10.5.3 South and Central America Postmenopausal Vaginal Atrophy Therapeutics Market Forecasts and Analysis - By Therapy type
10.5.4 South and Central America Postmenopausal Vaginal Atrophy Therapeutics Market Forecasts and Analysis - By Product types
10.5.5 South and Central America Postmenopausal Vaginal Atrophy Therapeutics Market Forecasts and Analysis - By End User
10.5.6 South and Central America Postmenopausal Vaginal Atrophy Therapeutics Market Forecasts and Analysis - By Countries
10.5.6.1 Brazil Postmenopausal Vaginal Atrophy Therapeutics Market
10.5.6.1.1 Brazil Postmenopausal Vaginal Atrophy Therapeutics Market by Therapy type
10.5.6.1.2 Brazil Postmenopausal Vaginal Atrophy Therapeutics Market by Product types
10.5.6.1.3 Brazil Postmenopausal Vaginal Atrophy Therapeutics Market by End User
10.5.6.2 Argentina Postmenopausal Vaginal Atrophy Therapeutics Market
10.5.6.2.1 Argentina Postmenopausal Vaginal Atrophy Therapeutics Market by Therapy type
10.5.6.2.2 Argentina Postmenopausal Vaginal Atrophy Therapeutics Market by Product types
10.5.6.2.3 Argentina Postmenopausal Vaginal Atrophy Therapeutics Market by End User
11. IMPACT OF COVID-19 PANDEMIC ON GLOBAL POSTMENOPAUSAL VAGINAL ATROPHY THERAPEUTICS MARKET
11.1 North America
11.2 Europe
11.3 Asia-Pacific
11.4 Rest of the World
12. INDUSTRY LANDSCAPE
12.1. MERGERS AND ACQUISITIONS
12.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
12.3. NEW PRODUCT LAUNCHES
12.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
13. POSTMENOPAUSAL VAGINAL ATROPHY THERAPEUTICS MARKET, KEY COMPANY PROFILES
13.1. ENDOCEUTICS
13.1.1. Key Facts
13.1.2. Business Description
13.1.3. Products and Services
13.1.4. Financial Overview
13.1.5. SWOT Analysis
13.1.6. Key Developments
13.2. ACCORD HEALTHCARE
13.2.1. Key Facts
13.2.2. Business Description
13.2.3. Products and Services
13.2.4. Financial Overview
13.2.5. SWOT Analysis
13.2.6. Key Developments
13.3. PFIZER
13.3.1. Key Facts
13.3.2. Business Description
13.3.3. Products and Services
13.3.4. Financial Overview
13.3.5. SWOT Analysis
13.3.6. Key Developments
13.4. NOVO NORDISK
13.4.1. Key Facts
13.4.2. Business Description
13.4.3. Products and Services
13.4.4. Financial Overview
13.4.5. SWOT Analysis
13.4.6. Key Developments
13.5. TEVA PHARMACEUTICALS
13.5.1. Key Facts
13.5.2. Business Description
13.5.3. Products and Services
13.5.4. Financial Overview
13.5.5. SWOT Analysis
13.5.6. Key Developments
13.6. SHIONOGI AND CO
13.6.1. Key Facts
13.6.2. Business Description
13.6.3. Products and Services
13.6.4. Financial Overview
13.6.5. SWOT Analysis
13.6.6. Key Developments
13.7. BIONOVO, INC.
13.7.1. Key Facts
13.7.2. Business Description
13.7.3. Products and Services
13.7.4. Financial Overview
13.7.5. SWOT Analysis
13.7.6. Key Developments
13.8. QUATRX PHARMACEUTICAL COMPANY
13.8.1. Key Facts
13.8.2. Business Description
13.8.3. Products and Services
13.8.4. Financial Overview
13.8.5. SWOT Analysis
13.8.6. Key Developments
13.9. BAYER AG
13.9.1. Key Facts
13.9.2. Business Description
13.9.3. Products and Services
13.9.4. Financial Overview
13.9.5. SWOT Analysis
13.9.6. Key Developments
13.10. THERAPEUTICSMD
13.10.1. Key Facts
13.10.2. Business Description
13.10.3. Products and Services
13.10.4. Financial Overview
13.10.5. SWOT Analysis
13.10.6. Key Developments
14. APPENDIX
14.1. ABOUT THE INSIGHT PARTNERS
14.2. GLOSSARY OF TERMS
The List of Companies

1. Endoceutics
2. Accord Healthcare
3. Pfizer
4. Novo Nordisk
5. Teva Pharmaceuticals
6. Shionogi and Co
7. Bionovo, Inc.
8. QuatRx Pharmaceutical Company
9. Bayer AG
10. TherapeuticsMD
TIPRE00013446
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Pricing

Free

20%

customization on Pre-Booking